Pomerantz Law Firm Announces Class Action Lawsuit Against Actinium Pharmaceuticals for Investor Losses

Investor Alert: Class Action Lawsuit Against Actinium Pharmaceuticals

Overview

Pomerantz Law Firm has recently announced a class action lawsuit against Actinium Pharmaceuticals, Inc. (NYSE: ATNM), calling attention to the significant loss incurred by investors. The firm is encouraging those affected to reach out to their legal team before the deadline on May 26, 2025.

Background of the Case

The lawsuit centers around allegations that Actinium and its executives engaged in securities fraud and other questionable business practices. The urgency of this lawsuit was amplified when Actinium made an announcement on August 5, 2024, regarding the Biologics License Application (BLA) for its treatment, Iomab-B, targeted at patients suffering from active relapsed or refractory acute myeloid leukemia (r/r AML).

Despite favorable initial results from the Phase 3 SIERRA trial, which met its primary endpoint statistically, the U.S. Food and Drug Administration (FDA) determined that the trial results were insufficient for the BLA filing. Following this announcement, Actinium's stock price plummeted nearly 60%, causing significant financial loss for shareholders as it closed at just $2.48 per share.

Investor Participation

Investors who acquired Actinium’s securities during the Class Period are eligible to ask the court to appoint them as Lead Plaintiffs. This crucial step allows investors to take an active role in the proceedings. Those interested should contact Danielle Peyton at Pomerantz LLP, providing their contact details and the number of shares purchased to ensure they are included in the litigation process.

The Role of Pomerantz Law Firm

Founded over 85 years ago by the late Abraham L. Pomerantz, the firm is considered a leader in corporate and securities law. They specialize in class action litigation, fighting for the rights of those who have suffered financial losses due to fraudulent practices and breaches of fiduciary duties. Pomerantz’s established record of securing multimillion-dollar settlements speaks to their commitment to achieving justice for affected investors.

How to Get Involved

For further information and to join the class action, interested investors can visit Pomerantz's official website or call directly for guidance. The firm has made provisions to assist investors in navigating the complexities of the legal process, ensuring that they are well-represented as the case unfolds.

Conclusion

With the impending deadline approaching, it is vital for those who have suffered losses in Actinium Pharmaceuticals to act swiftly. Engaging with Pomerantz Law Firm can provide not only support but also a pathway to potential compensation for unjust losses. Time is of the essence, urging affected investors to seek legal advice without delay.